Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Nightingale secured a 0.7 MEUR agreement for the Italian Moli-sani study

By Frans-Mikael RostedtAnalyst
Nightingale Health

Translation: Original published in Finnish on 07/07/2025 at 09:03 am EEST

Nightingale was selected as the metabolomics analysis provider for the renowned Moli-sani study in Italy. The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. The agreement is significant for the company's research business and supports our growth forecasts for the second half of 2025. The company's revenue from other European countries (including Italy) was some 0.8 MEUR in 2024, making the agreement a significant size in comparison. This is a project-based revenue item, but we believe the agreement is a good additional reference for Nightingale's technology.

The Moli-sani study, led by INM Neuromed, investigates risk factors associated with major chronic diseases. With Nightingale Health’s advanced technology, the study will now examine the impact of nutritional and environmental factors on health.   The study also explores biological signatures associated with healthy aging and aims to identify population subgroups with different responses to preventative interventions. Nightingale was selected for the project in accordance with Italian public procurement law, and the parties are now proceeding to finalize the service agreement.

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures11.06.2025

202425e26e
Revenue4.45.28.2
growth-%4.2 %19.5 %57.5 %
EBIT (adj.)-18.6-17.3-16.2
EBIT-% (adj.)-426.6 %-331.4 %-197.6 %
EPS (adj.)-0.29-0.27-0.25
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

The Pathology Asia/Innoquest entity would certainly have been interesting, but it was left off the question list this time due to prioritization...
1/2/2026, 7:04 AM
by Antti Luiro
6
@Antti_Luiro thanks for the interview. A nice extra episode. I listened to it again carefully and it started sounding a bit better than the ...
12/31/2025, 8:04 AM
by Cle
5
I hope that in the near future, the Medical Director they are currently recruiting will be the one communicating about these clinical applications...
12/23/2025, 5:21 PM
by omegaalpha
0
I’m clinging to this numerical “ten pilot cases during the spring” and the 50% revenue growth target like a drowning man to a stick, even though...
12/23/2025, 3:19 PM
by Cle
2
Thanks for the interview. So it is progressing, but this certainly is a long game, as has been communicated. Now, with the goal for 2026 being...
12/23/2025, 6:40 AM
by Puutaheinää
8
I went to ask Teemu about news from the autumn and early winter on video Merry Christmas to the thread! Inderes Nightingale Health: Kaupalliset...
12/22/2025, 7:53 PM
by Antti Luiro
19
@Homeros This 2022 Nature article was not written by people working at NG. It was the 2023 Nature article. Additionally, it is sometimes forgotten...
12/20/2025, 4:25 PM
by Monsieur
3
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.